Table 2.
Relative expression of tenascin-C, AD1 and AD2 in cell lines and isolated normal breast cells
| Number of TNC transcripts (×10 3 ) | % of total TNC transcripts | ||||
|---|---|---|---|---|---|
| Cell line | Total TNC | AD1 | AD2 | AD1 | AD2 |
| ZR-75-1 | 0 | 0 | 0 | 0 | 0 |
| T-47D | 0 | 0 | 0 | 0 | 0 |
| MCF-7 | 0 | 0 | 0 | 0 | 0 |
| Hs578T | 162.651 | 41.432 | 14.574 | 25.47 | 8.96 |
| MDA-MB-231 | 1,293.947 | 44.383 | 23.821 | 3.43 | 1.84 |
| MDA-MB-436 | 8,409.526 | 479.824 | 55.735 | 5.71 | 0.66 |
| MDA-MB-468 | 984.727 | 89.74 | 28.784 | 9.11 | 2.92 |
| GI-101 | 1,529.834 | 143.854 | 8.433 | 9.40 | 0.55 |
| HBL-100 | 15,017.045 | 6,671.261 | 483.212 | 44.42 | 3.22 |
| MCF-10A | 91.37 | 7.399 | 6.933 | 8.10 | 7.59 |
| Primary MEC | 2,925.394 | 1,863.143 | 142.39 | 63.69 | 4.87 |
| Primary fibroblasts | 5398.821 | 87.867 | 98.044 | 1.63 | 1.82 |
Percentage expression of additional domain (AD) 1 and AD2 relative to the invariant exon 17/18 boundary, as a marker of total tenascin-C (TNC) expression, normalised to the hypoxanthine phosphoribosyltransferase 1 control in cell lines and isolated normal breast cells. MEC, myoepithelial cells.